EATG » R&D

R&D

Inovio and The Wistar Institute to advance vaccines against TB & malaria

Inovio and The Wistar Institute receive more than $4.6 million in R&D funding to advance vaccines against TB & malaria PLYMOUTH MEETING, Pa., Feb. 12, 2018 -- Inovio Pharmaceuticals, Inc.…

Otsuka to advance development of novel TB compound

Otsuka awarded grant to advance development of novel TB compound OPC-167832 with delamanid TOKYO, Japan & PRINCETON, NJ, USA I January 29, 2018 -- Otsuka Pharmaceutical Co., Ltd., and its…

EFGCP Conference Coming Up in February

The upcoming conference of the European Forum for Good Clinical Practice holds its next conference in Brussels in February 2018. The conference will pay special attention to the consequences of…

R&D for neglected diseases reliant on just two donors, G-FINDER report warns

LONDON, 14 December 2017 — Funding for research and development into neglected diseases has increased for the first time in recent years, driven by investments from the United States, a new…

WHO policy paper calls for increased investments in TB research to reach end TB targets

28 November 2017 | Geneva: The World Health Organization released a policy paper during the First WHO Global Ministerial Conference on Ending TB on 17 November, highlighting the persistent investment gaps…

Vital microbicides may soon be out of reach

Whether, when, and how microbicide development proceeds depends on the U.S government, and the federal Division of AIDS has suggested this development may no longer be a priority. It's wrong.…

TAG releases new report on TB research funding

Higher funding for TB research signals hope, but governments must dramatically increase spending to end TB. Before the World Health Organization Global Ministerial Conference on Ending TB in the Sustainable…

The world is running out of antibiotics, WHO report confirms

20 September 2017 | Geneva - A report, Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis, launched today by WHO shows a…

Immunocore and the Bill & Melinda Gates Foundation collaborate to develop immunotherapies for infectious diseases

$40 million investment to accelerate development of Immunocore’s ImmTAV® and ImmTAB® therapeutics for infectious diseases, in particular tuberculosis and HIV (Oxford, UK and Conshohocken, US 18 September 2017) Immunocore Limited,…

Declining funding and shrinking donor base imperils continued success of HIV prevention research

European countries called to renew support New York and Paris, July 20, 2017 — A new report released today ahead of the 9th IAS Conference on HIV Science documents 2016 funding…

1 2 3 5